¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-20
±³À°ÀÏÀÚ : 2024-04-20
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾Å¸ AIȦ

±³À°ÁÖÁ¦ : 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼ºÀÎALL¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 70¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í ºñȸ¿ø 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 10:00~10:30 "CAR T cell therapy in adult ALL(acute lymphoblastic leukemia) " ¹éµ¿ÈÆ(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 10:30~11:00 "ASH guidelines for adolescents and young adults ALL (acute lymphoblastic leukemia) " ±èµµ¿µ(ºÎ»êÀÇ)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 11:10~11:40 Recent diagnostic advances in adults ALL(acute lymphoblastic leukemia) ÀÌÁ¾¹Ì(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 11:40~12:10 Recent therapeutic advances in adults ALL(acute lymphoblastic leukemia) ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 13:10~13:50 Advances in gene-engineered immune cells of cancer therapy ÀÌÇý¼±(KAIST)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 13:50~14:30 Global trends of CAR T cell therapy in cancer Á¶¼öÈñ(CuroCell)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 14:50~15:05 Updated clinical outcomes & predictive factors to blinatumomab in patients with relapsed/refractory BCP-ALL ¹éµ¿¿ø(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:05~15:20 Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) º¯ÀÚ¹Î(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:20~15:30 A phase 2 clinical trial to evaluate the efficacy of Venetoclax and Decitabine in relapsed/refractory adult T acute lymphoblastic leukemia/lymphoma (VEDETTE Study) ½Åµ¿¿±(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:30~15:40 Post-transplant therapy with hypomethylating agent in Philadelphia chromosome negative adult acute lymphoblastic leukemia ¹éµ¿¿ø(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:40~15:50 "Ponatinib based induction therapy followed by allogeneic stem cell transplantation with pre-emptive use of ponatinib for patients with Philadelphia positive B-cell acute lymphoblastic leukemia, prospective, multicenter study " ¹éµ¿¿ø(°æºÏÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ16th Vascular Ultrasound Seoul Update 2023 Symposium (1ÀÏÂ÷) : 2024-04-20
´ÙÀ½±Û (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù) : 2024-04-20 [1]
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
219 ÀÎõ Á¦3ȸ ÀÎÇϴ뺴¿ø ¼Ò¾Æû¼Ò³â°ú ±³À°°­Á : 2018-09-08 0 846 2018-07-28
218 ¼­¿ï Á¦ 19ȸ ´ëÇÑÅõ¼®Çùȸ Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-08 1 674 2018-07-28
217 ¼­¿ï ´ëÇѽÉÀåÇÐȸ EP Review Course 2018-2 : 2018-09-08 0 943 2018-07-28
216 ÀüºÏ 2018³â Á¦29ȸ ´ëÇÑ°£ÇÐȸ Ãß°è Single Topic Symposium ¹× ÃÊÀ½ÆÄ Hands-on : 2018-09-08 0 372 2018-07-28
215 ÀÎõ 2018³â ±¹Á¦¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-08 0 539 2018-07-28
214 ÀÎõ °¡ÃµÀÇ´ë±æº´¿ø È£½ºÇǽº ¿ÏÈ­ÀÇ·á Á¤Âø°ú È®´ë¸¦ À§ÇÑ ÀÎõÁö¿ª¾Ï¼¾ÅÍ ½ÉÆ÷Áö¿ò : 2018-09-08 0 1,210 2018-07-28
213 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª : 2018-09-07 0 304 2018-07-28
212 °æ±â ¸íÁöº´¿ø The 3nd MYONGJI INTERNATIONAL LIVER SYMPOSIUM : 2018-09-07 0 389 2018-07-28
211 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/07 : 2018-09-07 0 470 2018-07-28
210 ¼­¿ï 2018³â ¼­¿ï¾Æ»êº´¿ø ¾Ïº´¿ø ½ÉÆ÷Áö¾ö : 2018-09-07 0 486 2018-07-28
209 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ 2018³â ¹Î°£¡¤°ø°øÇù·Â(PPM) ±¹°¡°áÇÙ°ü¸®»ç¾÷ Æò°¡´ëȸ : 2018-09-07 0 553 2018-07-28
208 ´ë±¸ ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(4Â÷: °æ»óÁ¦ÁÖ±Ç) : 2018-09-07 0 592 2018-07-28
207 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-07 0 281 2018-07-28
206 ¼­¿ï °í·Á´ëÇб³¾È¾Ïº´¿ø ÀÏÂ÷ ÀÇ·áÁø°ú ÇÔ²²ÇÏ´Â ½É¹æ¼¼µ¿ÀÇ Ä¡·á : 2018-09-07 0 525 2018-07-28
205 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] ÀÇ·á»ç°í¿Í Á¶Á¤ ÁßÀç / ¼³¸íÀǹ« : 2018-09-06 0 375 2018-07-28
1361 | 1362 | 1363 | 1364 | 1365 | 1366 | 1367 | 1368 | 1369 | 1370
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷